Infectech, Inc. (pinksheets:IFEC), a biotechnology / genomics company in research, development, and production of kits used in the rapid identification and antibiotic testing of disease-causing pathogens, today announced that it has engaged Lake Erie Research Institute, Inc. (LERI) to assist in all FDA device and 510K submissions required for the company to begin commercializing its technologies covered by 32 patents. Infectech anticipates filing our first documentation before the end of the year.
"Dr. Kuhn's assistance with FDA submissions will be an invaluable resource to Infectech," stated Dr. Mitchell Felder, Infectech's Chief Executive Officer. "Dr. Kuhn will help Infectech prepare for registration and commercialization of its technologies," he added.
"I look forward to working with Infectech. The request for assistance aligns with the mission of the Lake Erie Research Institute, which is to promote high quality medical research and medical product development." stated Dr. Phyllis Kuhn. "I look forward to their achieving great success in this endeavor," she added.
About Infectech
Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious human diseases. The Company's patents span the identification and antibiotic sensitivity testing of 34 disease-producing bacteria, including tuberculosis (TB), Mycobacterium avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are cited as prominent causes of morbidity and mortality in patients with cancer, cystic fibrosis, and AIDS.
About Lake Erie Research Institute
The Lake Erie Research Institute (LERI) is a 501(c) (3) independent, not-for-profit entity whose mission is to foster high quality, health and medically related research and entrepreneurial development. LERI provides wrap-around research services, such as protocol development, statistical analysis, grant writing, business plan development, technology transfer, and other needed expertise. (Contact information: Pkuhnphd@aol.com).
www.infectech.com
Safe Harbor under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, regulatory approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties as may be detailed in the Company's filings with the Securities and Exchange Commission. Nothing in this press release shall be construed as an offer to buy or sell any securities herein.